BIOTOOL-CHF will discover, develop, and validate a personalised approach to manage diuretic therapy in heart failure and reduced ejection fraction, to reduce heart failure hospitalizations and improve quality of life
BIOTOOL-CHF gathers major European heart failure and big data analysis experts to provide an innovative approach to the management patients with heart failure and reduced ejection fraction, which is one of the most frequent, costly and deadly pathological conditions in Europe
BIOTOOL-CHF partners join forces to change the paradigm of heart failure with reduced ejection fraction pharmacological therapy, by developing a personalised strategy to target congestion with diuretics.
PROJECT NUMBER: 101095653 PROJECT TITLE: BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure TOPIC: HORIZON-HLTH-2022-TOOL-11-01 START DATE: 1 October 2023 DURATION: 60 Months GRANTING AUTHORITY: HADEA EU CONTRIBUTION: 9.600.663,00 Euro
“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do notnecessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.”